



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

Dec. 28, 2006 Paula S. Linkhart
Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert F. Garry

Russell B. Wilson

Serial No.: **10/578,013**

Filed: **May 3, 2006**

Confirmation No.: **3051**

For: **METHOD OF PREVENTING VIRUS:CELL
FUSION BY INHIBITING THE FUNCTION
OF THE FUSION INITIATION REGION IN
RNA VIRUSES HAVING CLASS 2
MEMBRANE FUSOGENIC ENVELOPE
PROTEINS**

§ Group Art Unit: **1648**

§

§ Examiner:

§

§ Atty. Dkt. No.: **12920.0013.PCUS00**

§

§

§

§

§

§

§

§

§

§

§

§

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached forms PTO-SB/08A and SB/08B be considered by the Examiner and made of record in the current application. Supplied herewith are copies of references B1, B2 and C1-C3, and a

IDS

copy of the Search Report/Written Opinion dated 29 September 2006 issued from the international phase of this application.

In accordance with 37 C.F.R. § 1.97(g) and (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, or as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this paper is being filed before an Office Action on the merits of the application has been sent; therefore no fee is believed to be due. However, should any fees be required for any reason in connection with this paper, the Commissioner is authorized to deduct said fees from Howrey Deposit Account No. 08-3038/12920.0013.PCUS00.

Respectfully submitted,



Patricia A. Kammerer.

Reg. No. 29,775

Attorney for Assignee

THE ADMINISTRATORS OF THE
TULANE EDUCATIONAL FUND

Customer No. 23369
HOWREY LLP
1111 Louisiana, 25th Floor
Houston, Texas 77002
(713) 787 1400

Date: December 28, 2006

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 1

Complete if Known

Application Number	10/578,013
Filing Date	May 3, 2006
First Named Inventor	Robert F. Garry
Art Unit	1648
Examiner Name	
Attorney Docket Number	12920.0013.PCUS00

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	B1	WO 2005/010034 A1	02-03-2005	Natl Institutes of Health		
	B2	WO 2005/016238 A2	02-24-2005	Duke University		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/578,013
Filing Date	May 3, 2006
First Named Inventor	Robert F. Garry
Art Unit	1648
Examiner Name	
Attorney Docket Number	12920.0013.PCUS00

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ATABANI, et al., Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection, Journal of Virology, 1997, 71(10):7240-7245.	
	C2	SAMUEL, et al., Participation of two fusion peptides in measles virus-induced membrane fusion: emerging similarity with other paramyxoviruses, Biochemistry, 2001, 40:1340-1349.	
	C3	KLIGER, et al., Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy, BMC Microbiology, 2003, 3:20.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.